Oral propranolol therapy in parotid hemangiomas: A retrospective comparison with other infantile hemangiomas

Head & Neck ◽  
2021 ◽  
Author(s):  
Luying Wang ◽  
Shaohua Li ◽  
Qianqian Gao ◽  
Renrong Lv ◽  
Guangqi Xu ◽  
...  
2018 ◽  
Vol 2018 ◽  
pp. 1-6
Author(s):  
Chuan Wang ◽  
Qi Wang ◽  
Bo Xiang ◽  
Siyuan Chen ◽  
Fei Xiong ◽  
...  

Background. The aim of this study was to examine whether oral propranolol has any effect on neurodevelopment outcomes in young children with problematic infantile hemangiomas (IHs). Methods. Thirty-six children with a diagnosis of problematic IH who were treated with oral propranolol were compared with 34 healthy children with no history of propranolol therapy. Patients received propranolol therapy for at least 3 months. Gesell developmental schedules (GDS) were used to evaluate neurodevelopment outcomes in the two groups. The scores of each GDS domain were compared between the two groups. Results. There were no significant differences in developmental quotient (DQ) values for any of the five domains between the patients and healthy controls (P<0.05). Multiple stepwise regression analyses showed that none of the domains in the control group were influenced by the children’s gender or age (P<0.05). In addition, we found that gender, age at the initiation of therapy, age at the time of the neurodevelopment test, and treatment duration had no effect on any domain of the GDS in the patient group (P>0.05). Conclusion. Propranolol has no obvious effect on neurodevelopmental outcomes in children. Early treatment and treatment duration had no negative effect on central nervous system (CNS) development.


2020 ◽  
Vol 156 (2) ◽  
pp. 186 ◽  
Author(s):  
Gerilyn M. Olsen ◽  
Leanna M. Hansen ◽  
Nicole S. Stefanko ◽  
Erin Mathes ◽  
Katherine B. Puttgen ◽  
...  

Author(s):  
Mustafa Dilek ◽  
Mervan Bekdaş ◽  
Sevil Bilir Göksügür ◽  
Fatih Demircioğlu ◽  
Zehra Karataş ◽  
...  

Author(s):  
Giovanni Frongia ◽  
Ji-Oun Byeon ◽  
Arianeb Mehrabi ◽  
Patrick Günther

2018 ◽  
Vol 14 (3) ◽  
pp. 254-258 ◽  
Author(s):  
Giovanni Frongia ◽  
Ji-Oun Byeon ◽  
Raoul Arnold ◽  
Arianeb Mehrabi ◽  
Patrick Günther

2019 ◽  
Vol 3 (2) ◽  
Author(s):  
Ioannis Polymerou ◽  
Tiina Ojala ◽  
Pipina Bonou ◽  
Laura Martelius ◽  
Aphrodite Tzifa

AbstractBackgroundCardiac haemangiomas are extremely rare tumours with equivocal surgical outcomes. Haemangiomas appearing on other sites of the body have been successfully treated with oral propranolol. To the best of our knowledge, such treatment has not been tried to date for cardiac location of haemangiomas.Case summaryWe report two cases of neonatal cardiac haemangiomas, and we describe their presentation and characteristics, as well as how these were successfully treated with oral propranolol, with complete regression of the tumours within the 1st year of life.DiscussionDespite the rarity of cardiac haemangiomas, their presentation and complications could be dramatic with side-effects spanning from intracardiac space occupying phenomena to Kasabach–Merritt syndrome. Propranolol therapy, having been established for long now in the treatment of skin haemangiomas, should also be considered in cases of cardiac haemangiomas, particularly in the neonatal and infantile population.


1975 ◽  
Vol 35 (5) ◽  
pp. 635-644 ◽  
Author(s):  
William Frishman ◽  
Charles Smithen ◽  
Barbara Befler ◽  
Paul Kligfield ◽  
Thomas Killip

2018 ◽  
Vol 32 (2) ◽  
pp. 34-37
Author(s):  
Gerardo Aniano C. Dimaguila ◽  
Emmanuel S. Samson

Objective: To describe outcomes of oral propranolol therapy in a series of adult and pediatric patients diagnosed with benign capillary hemangioma of the head and neck. Methods:             Design:           Prospective Case Series             Setting:           Tertiary Government Hospital Participants: Ten (10) patients representing all patients clinically diagnosed with benign capillary hemangioma of the head and neck, enrolled in the study from 2012 to 2015. Results: Two (2) adults and eight (8) children were enrolled in the study. Although a decrease in lesion size was observed in half of the participants starting at three months, only one (1) attained complete resolution of the lesion-- a 12-year-old girl with hemangioma of the right parotid gland that attained clinical resolution of symptoms after four months of treatment. The remaining nine out of ten (9/10) participants did not attain complete clinical resolution; but there was a decrease in lesion size in four (4) of these participants. For the remaining five (5) participants, there was neither a decrease nor an increase in lesion size. Altogether, of the two adult participants, only one responded to therapy, while only 4 out of 8 pediatric participants responded to therapy. There were no noticeable differences between adult and pediatric patients in terms of resolution and plateau. Aside from mild bradycardia expected with propranolol, no adverse reactions were observed during the course of treatment. Conclusion: Although half of our participants responded to oral propranolol therapy, whether these observations may be attributable to oral propranolol alone cannot be concluded. Keywords: hemangioma, capillary; hemangioma; propranolol administration, oral; propranolol


2018 ◽  
Vol 43 (1) ◽  
pp. 44-50
Author(s):  
Nirupama Saha ◽  
Shah Alam Talukder ◽  
Nadiuzzaman Khan

Infantile hemangiomas are the most common vascular tumor of infancy and childhood. Sometimes these lesions interfere with normal function & produce serious disfigurement that is unlikely to resolve on its own and then treatment is required. While evidence most supports the use of corticosteroids, there is no well- studied or Federal Drug Administration (FDA) approved systemic therapy for haemangiomas of Infancy. Dramatic improvement of complicated haemangioma by propranolol has recently been reported, but to date, details for initiating therapy, monitoring and potential risks in relation to Corticosteroids were not compared in a large scale. This research was designed to observe the effectiveness of oral propranolol compared to oral corticosteroid aimed at treatment of clinically important groups of infantile hemangiomas that require aggressive treatment. We conducted a randomized control study among the diagnosed case of infantile hemangiomas, age of <10 years. The total sample size was 60 (30 for propranolol group i.e. in group A, and 30 for corticosteroid group i.e. in group B) & grouping was done with the simple random technique. A clinical & photograph based VAS (Visual Analogue Scale) scale with a defined monitoring schedule was used for evaluation of treatment response. Our study result showed, (3.33%) patients of group A, response to color change (red-purple-grey) within 1st month of treatment whereas none of the patient (0.00%) of group B had any response to color by this time. Patients response to propranolol therapy was also continued even up to 5th month (3.33%) but it was absent (0.00%) in corticosteroid therapy even after 4th month & p= 0.025, that was statistically significant. Regarding the mean size (diameter) of the tumor, most of the tumor size reduced and near to stabilize at 4th month in group A, but in group B, the rate was slower and needed longer time (5-6 month), the p value was 0.030. Again 60% of tumor became non-palpable at 3rd week of treatment in group A patients, but in group B, 70% of tumor was still remain palpable on that time & p=0.001, that was statistically significant. Again, in Propranolol therapy group, the rate of complications was (24%) whereas in Corticosteroid therapy group, it was (76%).The p value was 0.020 that was also statistically significant. Hence, the present study results denote that, oral propranolol can be considered as an emerging and effective treatment over oral corticosteroid therapy for infantile hemangiomas.


Sign in / Sign up

Export Citation Format

Share Document